Drug intelligence / Profile preview

RK004

Development stage: Preclinical
Lead developer: RevolKa
Modality: Recombinant Proteins and Enzymes

Overview

RK004 is an experimental protein-based therapeutic candidate being developed by RevolKa. It was generated using RevolKa's proprietary protein engineering technology, which utilizes a high-throughput directed evolution platform to optimize protein functions. While the specific molecular target and therapeutic indication for RK004 have not been publicly disclosed, the candidate is part of a broader pipeline of engineered proteins and antibodies. As of the latest reports, RK004 has completed an undisclosed stage of early-stage research or technology development.

Beyond the preview

Go deeper on RK004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RK004.

Explore the full profile